Pharma News

New drug approved for treating psoriatic arthritis by FDA

The U.S. Food and Drug Administration approved Otezla (apremilast), manufactured for Celgene Corporation, Summit, N.J.,  to treat adults with active psoriatic arthritis (PsA), which is a form of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with PsA. Joint pain, stiffness and swelling are the main signs and symptoms of PsA.

India reaches remarkable milestone as 'Polio Free Nation' certified by WHO

On thursday, 27th march 2014, the World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status. India is among other countries in its South East Asian region which have been certified as being free of the wild polio virus. Ghulam Nabi Azad, health minister of India, received the official certificate from WHO.

FDA approves first implantable hearing device

The U.S. Food and Drug Administration approved the first implantable device for people 18 and older with severe or profound sensorineural hearing loss of high-frequency sounds in both ears, but who can still hear low-frequency sounds with or without a hearing aid. The Nucleus Hybrid L24 Cochlear Implant System may help those with this specific kind of hearing loss who do not benefit from conventional hearing aids.

Scientists identified genetic diversity of K.Pneumoniae (drug-resistant bacteria)

New findings, by group of scientists, will facilitate the development of new clinical strategies design to prevent or treat infections caused by multidrug-resistant Klebsiella Pneumoniae. Scientists from National Institutes of Health (NIH) and their colleagues have tracked the evolution of the Carbapenem-resistant bacterium K.pneumoniae sequence type 258 (ST258), an important agent of hospital-acquired infections by using genome sequencing.

Health Ministry notified on implementation of Schedule H1 drugs in D&C rules | No more OTC selling of antibiotics

The Drugs and Cosmetics Rules, 1945 (D&C rules) were amended vide Drugs and Cosmetics (Fourth Amendment) Rules, 2013 published under Gazette notification G.S.R. 588(E) dated 30.08.2013 regarding the inclusion of Schedule H1 under the D&C rules containing certain antibiotics, anti-TB drugs and habit forming drugs. The notification states that these rules will come into force after six months of their publication in the official Gazette i.e. from 1st March, 2014

New discovery can delay Alzheimer's development

Researchers from Michigan University have found out cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and looks like major cause of Alzeimer's Disease (AD). this mechanism helps decode amyloid plaque formation in the brains of Alzheimer's patients—plaques that kills cells and contributes to memory loss and other Alzheimer's symptoms.
The researchers discovered the molecular process behind Golgi fragmentation, and also developed two techniques to 'rescue' the Golgi structure.

Government lifting ban from Analgin

Indian health ministry revoked the ban from Analgin, potent analgesic and antipyretic. Last year in June 2013, government issued a ban on manufacturing and selling of analgin in country because it is involved in risk to human beings and whereas safer alternatives of analgin are available. After revoking ban from pioglitazone, this is the second time when ministry has lifted ban from a drug.

U.S. FDA approval for Eliquis® (apixaban) to reduce risk of thrmobosis in Hip or Knee Replacement Surgery

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.